Video Series

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).

Syma Iqbal, MD, shares final insights into the ESCC and GI cancer treatment landscape, emphasizing the utilization of key diagnostic tools and innovative treatment strategies.

Experts discuss the impact of supportive care in the MDS treatment landscape.

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.

Syma Iqbal, MD, discusses how ESCC and GI cancer treatment pathways may have a myriad of effects on patient quality of life.

A medical expert discusses treating patients with ESCC and GI cancers as recommended by current FDA and NCCN guidelines.

Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.

Expert panelists explore challenges impacting care access for patients with MDS.

In her final thoughts, Dr Oskouei discusses how patient care may be improved by increased access to biosimilars.

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.

Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo.

The panel discusses emerging treatments for vitiligo and addresses opportunities for payers to support implementation.

CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment.

Syma Iqbal, MD, provides an overview of the KEYNOTE-590 trial and its impact on treatment pathways for ESCC and GI cancers.

The esteemed panel concludes with their final thoughts on CKD therapies and management.

Drs Feldman, Pitt, and Agarwal describe the common CKD health disparities seen at their institutions and the steps they have taken to address them.

Paul Noble, MD, provides his closing thoughts on payer perspectives surrounding ILD, as well as considerations for the trajectory of ILD treatment landscape.

Nintedanib recommendations for use from the recent ATS guidelines and treatment implementation are considered by Paul Noble, MD.

Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.

Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.

Sonia Oskouei explores the managed care landscape and opportunities for increasing biosimilar uptake to improve patient care.

Evolving treatment strategies for esophagogastric cancer are explored by Syma Iqbal, MD, including unmet needs across the treatment landscape.

Syma Iqbal, MD, provides insights pertaining to various types of upper GI cancers, as well as primary characteristics and risk factors for these diseases.

Dr King presents interleukin-15, a non-JAK inhibitor therapy option for the treatment of vitiligo.

Safety considerations, particularly surrounding JAK inhibitors in vitiligo treatment, are emphasized by the panelists.

Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.

Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.

Dr Jeffrey Feldman discusses finerenone trial data and the role that it and SGLT2 inhibitors have played in patients with CKD.

Dr Noble discusses recent ATS guidelines regarding the use of pirfenidone in ILD.